NCT06864572Enrolling by invitationEarly phase 1
[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
Clinical Application of Dual-target Imaging Agent [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
Source: ClinicalTrials.gov · Last updated 7 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Preclinical studies have confirmed that \[68Ga\]Ga-P17-079 in both mouse prostate tumors and osseogenic metastases has high uptake and prolonged retention, which enables \[68Ga\]Ga-P17-079 to be fully absorbed by the lesions, and it is possible to detect bone metastases, prostate cancer primary sites, lymph node metastases and organ metastases at the same time in a single examination. It is a potential "killing two birds with one stone" imaging agent. At this stage, the clinical study of \[68Ga\]Ga-P17-079 in the diagnosis and treatment of metastatic prostate cancer as a self-made preparation is planned to be carried out in our hospital to further verify its clinical application value.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 19 Feb 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Prostate cancer
- NCT number
- NCT06864572
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 40
- From 1 Sept 2024 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Suffering from claustrophobia or other mental illness
- Other conditions deemed unsuitable for participation in the trial
Other
- Severe abnormal liver and kidney function
- Fertile subjects will need to use effective contraception during the study
- Unable to lie flat for half an hour
- Refused to join this clinical investigator
Who the study is looking for
- Male aged 18-85 years, expected survival ≥12 weeks.
- Patients who have not undergone chemoradiotherapy, feasible surgery or biopsy to obtain a pathological diagnosis or are highly suspected of malignancy according to clinical diagnostic criteria.
- At least one measurable target lesion was present according to RECIST1.1 criteria.
- Obtain written informed consent and be able to follow up
Age in the registry: 18 years to 85 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.